Medical information
Prevent, treat, cure: these are the 3 ambitions that define Sanofi's broad offering of over 400 medicines and other products.
Sanofi's vocation is to help people facing health problems. As a global biopharmaceutical company specializing in human health, we prevent disease with our vaccines and offer innovative treatments. We support people suffering from rare diseases, as well as the millions of people suffering from chronic illnesses.
Whether you're a healthcare professional or a patient, our Medical and Scientific Information Department will be happy to answer your questions.
Mail: infomed-dz@sanofi.com
Phone : +213 982 300 220
Pharmacovigilance
Pharmacovigilance ensures the continuous monitoring of undesirable effects, as well as situations involving safety risks, such as misuse, abuse, overdose, use during pregnancy or breastfeeding, and medication errors.
If you are a healthcare professional or a patient and would like to report an adverse event that occurred in a patient treated with one of Sanofi's products, whether or not it is mentioned in the package insert, summary of product characteristics or legal information, please contact us.
Pharmacovigilance is the discipline of "identifying, assessing, understanding and preventing adverse effects and risk arising from the use of medicines" (WHO 2014).
For Sanofi, the safety and well-being of patients is the top priority. This is why Sanofi's Pharmacovigilance department plays an essential role in ongoing monitoring, enabling the collection, analysis and compilation of all safety data relating to its products already on the market or in development, in compliance with local (transmission of unrecognized adverse reactions to the National Center for Pharmacovigilance and Matériovigilance) and International legal requirements.
Pharmacovigilance activities aim to detect unidentified adverse events during clinical development, but also to monitor the incidence of adverse events over time for each product, and to clarify the circumstances in which reported events occur.
Such monitoring of adverse events, but also of any risky situations such as misuse, abuse, overdose, use during pregnancy or breastfeeding, helps to ensure that the most effective products can be used wisely by the patients for whom they will be most beneficial.
We would be grateful if you would take an active part in optimizing the benefit/risk ratio of our products, by reporting to us without delay any cases of pharmacovigilance that you may observe with our products:
Tel: +213 982 300 220
Fax: 023531163
Mail: pharmacovigilance-dz@sanofi.com
Center National de Pharmacovigilance et Matériovigilance
CNPM, Sis Route Petit Staoueli (NIPA) Dely Ibrahim Alger,
Tel / Fax : 00213 23 36 75 02 / 00213 23 36 75 27 / 00213 23 36 75 29
Mail: cnpm@cnpm.org.dz